Eksenatid

Eksenatid (INN, Byetta, Bydureon) agonist je glukagonu sličnog peptida-1 (GLP-1 agonist). On pripada grupi mimetika inkretina. Ovaj lek je odobren aprila 2005. za lečenje dijabetes melitusa tipa 2.^[1][2][3]

Eksenatid

Klinički podaci
Robne marke	Byetta, Byetta (Amylin/Eli Lilly)
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	141758-74-9
ATC kod	A10BX04
DrugBank	DB01276
Hemijski podaci
Formula	C184H282N50O60S
Mol. masa	4186.6
Farmakokinetički podaci
Poluvreme eliminacije	2,4 h
Izlučivanje	Renalno
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Subkutano

Reference

1. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. PMID 16230722
2. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. edit
3. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. edit

Literatura

• Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
• Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Eksenatid na Wikimedijinoj ostavi

• Exenatide